Search results for: Health Care Systems

Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?

4 January 2024

…by Member States following their approval of the scheme. Funding is raised from health systems by delaying the introduction of generic or biosimilar versions of the products for which a…

Drivers of the Growth in Medicines Expenditure

1 October 1997

Increases in expenditure on medicines, above the level of increases in health care expenditure generally, are a feature of all Western health systems, including the UK’s. This paper examines the…

Benchmarking and Incentives in the NHS

5 January 2000

…the application of benchmarking in the UK National Health Service (NHS). A key… propper-article Carol Propper This paper examines general issues in the use of benchmarking as a measure of…

Prices, Competition and Regulation in Pharmaceuticals: A Cross-National Comparison

1 June 2000

…R&D that serve all consumers. The potential for price differences within the EU arises because health care is a national policy prerogative and different countries have pursued very different regulatory…

Reducing Harm to Patients in the National Health Service. Will the Government’s Compensation Proposals Help?

1 December 2003

The UK government hopes that the proposals in the report of the Department of Health’s Chief Medical Officer “Making Amends” (CMO, 2003) will make its NHS safer whilst ensuring that…

2022 Innovation Policy Prize

…of individuals’ willingness–to–pay for a marginal improvement in population health, while a supply–side approach assumes that the ‘threshold’ should reflect the health opportunity cost of reimbursing medicines within a budget constrained health care…

NICE at 25: HTA Methods Guidelines – Evolution, not revolution

1 May 2024

…health inequalities in health technology evaluations. NICE has done some research in the health inequalities space, but NICE’s position does not currently allow for a quantitative modifier for health inequalities…

The burden of LDL-cholesterol-driven atherosclerotic cardiovascular diseases

31 March 2026

…for approximately Int$680 billion in annual direct healthcare spending worldwide. When considering indirect costs—that is, foregone economic activity due to morbidity and mortality and as well as informal caregiving costs—ASCVD’s…

What NHS Trusts Can Do to Reduce Waiting Times for Cancer Treatment

2 January 2020

The NHS Improvement Economics team is part of the Strategy Directorate in NHS Improvement. NHS Improvement aims to implement changes to help improve both quality and efficiency. Recent research by…